MYOK
MyoKardia, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
Market Cap: 12 Billion
Primary Exchange: NASDAQ
Website: http://www.myokardia.com
Shares Outstanding: 53.3 Million
Float: 51.8 Million
Dividend: (%)
Beta: 1.0158303338382613
Sector: Health Technology
Industry: Pharmaceuticals: Other
Ethical Flags
Longest drawdown: 431 trading days
From: 2018-09-25 To: 2019-12-03
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|